Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 29: Line 29:
[[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]]
[[Cardiomyopathy medical therapy|Medical Therapy]] | [[Cardiomyopathy surgery|Surgery]] | [[Cardiomyopathy primary prevention|Primary Prevention]] | [[Cardiomyopathy secondary prevention|Secondary Prevention]] | [[Cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cardiomyopathy future or investigational therapies|Future or Investigational Therapies]]


<br>
<br>
<br>
== <b>2023 ESC Guideline Recommendations </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657  }} </ref>==  
== <b>2023 ESC Guideline Recommendations </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657  }} </ref>==  

Revision as of 08:31, 9 November 2023


For patient information click here

Cardiomyopathy
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium {Autopsy findings}.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy

CDC on Cardiomyopathy

Cardiomyopathy in the news

Blogs on Cardiomyopathy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub,MD; Mahshid Mir, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3], Raviteja Guddeti, M.B.B.S. [4]; Edzel Lorraine Co, DMD, MD[5]


Synonyms and keywords: Myocardiopathy; cardiac muscle disease; heart muscle disease.

Overview

Historical Perspective

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies


2023 ESC Guideline Recommendations [1]


Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.

Class I
1. It is recommended that all patients with cardiomyopathy and their relatives have access to multidisciplinary teams with expertise in the diagnosis and management of cardiomyopathies. (Level of Evidence: C)
2. Timely and adequate preparation for transition of care from pediatric to adult services, including joint consultations, is recommended in all adolescents with cardiomyopathy. (Level of Evidence: C)

Recommendations for Diagnostic Work-up in Cardiomyopathies.

Class I
1. It is recommended that all patients with suspected or established cardiomyopathy undergo systematic evaluation using a multiparametric approach that includes clinical evaluation, pedigree analysis, ECG, Holter monitoring, laboratory tests, and multimodality imaging. (Level of Evidence: C)
2. It is recommended that all patients with suspected cardiomyopathy undergo evaluation of family history and that a three- to four-generation family tree is created to aid in diagnosis, provide clues to underlying etiology, determine inheritance pattern, and identify at- risk relatives (Level of Evidence: C)

Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.

Class I
1. (Level of Evidence: C)

Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.

Class I
1. (Level of Evidence: B)

Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.

Class I
1. (Level of Evidence: B)

Recommendations for Computed Tomography and Nuclear Imaging

Class I
1. (Level of Evidence: B)

Recommendations for Genetic Counselling and Testing in Cardiomyopathies.

Class I
Genetic Counselling
1. (Level of Evidence: B)

Case Studies

Case #1

de:Kardiomyopathie nl:Cardiomyopathie no:Kardiomyopati simple:Cardiomyopathy sr:Кардиомиопатија sv:Hjärtmuskelsjukdom

Template:WikiDoc Sources

  1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C; et al. (2023). "2023 ESC Guidelines for the management of cardiomyopathies". Eur Heart J. 44 (37): 3503–3626. doi:10.1093/eurheartj/ehad194. PMID 37622657 Check |pmid= value (help).